Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
A phase 2 trial of SHR-A2102, Retlirafusp alfa in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects is a phase 2 interventional study registered as NCT07175220 by Jiangsu HengRui Medicine Co., Ltd., with 200 participants planned, started 2025-10-09 and due to reach its primary completion in 2028-10. Interventions recorded: SHR2554; SHR-A2102, SHR2554; Adabelimumab, SHR2554; SHR-1701. Conditions listed: Locally Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
- TrialA Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals.
- TrialA Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals.
- TrialSafety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
- TrialA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.